Literature DB >> 24507521

The epidemiology of multiple sclerosis: insights to disease pathogenesis.

Douglas S Goodin1.   

Abstract

The purpose of studying the epidemiology of multiple sclerosis (MS) is twofold. First, it is important to understand clearly the natural history of the illness in order to assist patients in making decisions about their future with respect to issues such as family planning, the importance of securing lifelong healthcare, their ability to get and maintain employment, and making appropriate choices of therapy for their particular circumstances. This is not to suggest that, even with the best possible information, the ultimate prognosis for any individual can be predicted with absolute accuracy. It cannot. Nevertheless, accurate information can be very helpful both to reassure patients that many individuals with MS do remarkably well in the long term (perhaps, especially, with current and future therapies) and also to empower individuals with respect to their ability to make their own life choices. Second, and arguably the more important purpose for studying the epidemiology of MS, is to gain insights to the underlying causes of the disease. Indeed, if the principal mechanisms of disease pathogenesis were to be understood clearly, then it might be possible to entertain notions of either a cure for existing disease or the primary prevention of future disease. Much of our current understanding of disease pathogenesis, as discussed in other chapters of this volume, has been derived from basic science investigations of animal models of MS such as experimental autoimmune encephalomyelitis (EAE), and these models have provided considerable insight both to the complexity of the mammalian immune system and to the mechanisms underlying its dysfunction in inflammatory autoimmune conditions. Nevertheless, MS is a disease of humans without any known, naturally occurring, counterpart in any nonhuman species. For this reason, the clues to disease pathogenesis provided by a study of basic epidemiologic facts regarding MS (and by a systematic consideration of their implications) are essential to a comprehensive understanding of the human illness we call MS.
© 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  EBV; Epstein Barr virus; MS; Multiple sclerosis; clinical; epidemiology; gender; genetics; incidence; infection; mortality; natural history; pathogenesis; presentation; prevalence; sex; smoking; stress; susceptibility; trauma; vitamin D

Mesh:

Year:  2014        PMID: 24507521     DOI: 10.1016/B978-0-444-52001-2.00010-8

Source DB:  PubMed          Journal:  Handb Clin Neurol        ISSN: 0072-9752


  38 in total

1.  Sexual Dysfunction and Depression in Individuals with Multiple Sclerosis: Is there a Link?

Authors:  Rocco Salvatore Calabrò; Margherita Russo
Journal:  Innov Clin Neurosci       Date:  2015 May-Jun

Review 2.  Distinguishing Susac's syndrome from multiple sclerosis.

Authors:  Katherine A Buzzard; Stephen W Reddel; Con Yiannikas; D Sean Riminton; Michael H Barnett; Todd A Hardy
Journal:  J Neurol       Date:  2014-12-30       Impact factor: 4.849

Review 3.  Multiple Sclerosis Functional Composite.

Authors:  Serkan Demir
Journal:  Noro Psikiyatr Ars       Date:  2018       Impact factor: 1.339

4.  Hormonal contraception and the development of autoimmunity: A review of the literature.

Authors:  William V Williams
Journal:  Linacre Q       Date:  2017-08-18

Review 5.  Lymphatics in Neurological Disorders: A Neuro-Lympho-Vascular Component of Multiple Sclerosis and Alzheimer's Disease?

Authors:  Antoine Louveau; Sandro Da Mesquita; Jonathan Kipnis
Journal:  Neuron       Date:  2016-09-07       Impact factor: 17.173

6.  Polypharmacy in Multiple Sclerosis: Current Knowledge and Future Directions.

Authors:  Joanie Thelen; Valeriy Zvonarev; Sarah Lam; Crystal Burkhardt; Sharon Lynch; Jared Bruce
Journal:  Mo Med       Date:  2021 May-Jun

7.  Cardiovascular Dysfunction in Multiple Sclerosis.

Authors:  Raluca Ileana Mincu; Lucia Stefania Magda; Maria Florescu; Andreea Velcea; Sorina Mihaila; Diana Mihalcea; Bogdan O Popescu; Adela Chiru; Cristina Tiu; Mircea Cinteza; Dragos Vinereanu
Journal:  Maedica (Bucur)       Date:  2015-09

8.  Disease-Modifying Therapies for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis.

Authors:  Marita Zimmermann; Elizabeth Brouwer; Jeffrey A Tice; Matt Seidner; Anne M Loos; Shanshan Liu; Richard H Chapman; Varun Kumar; Josh J Carlson
Journal:  CNS Drugs       Date:  2018-12       Impact factor: 5.749

9.  Orofacial evaluation in patients with multiple sclerosis using Nordic Orofacial Test-Screening.

Authors:  Marcela Leticia Leal Gonçalves; Cristiane Miranda França; Yara Dadalti Fragoso; Alessandro Melo Deana; Larissa Mateus de Almeida; Sandra Kalil Bussadori
Journal:  Clin Oral Investig       Date:  2016-09-06       Impact factor: 3.573

Review 10.  Treatment strategies for multiple sclerosis: When to start, when to change, when to stop?

Authors:  Alberto Gajofatto; Maria Donata Benedetti
Journal:  World J Clin Cases       Date:  2015-07-16       Impact factor: 1.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.